# The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

> **NCT06044467** · PHASE1 · COMPLETED · sponsor: **ChemomAb Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Anti-human CCL24 monoclonal antibody (CM-101) - Part One
- **DRUG:** Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
- **DRUG:** Placebo - Study Part One
- **DRUG:** Placebo - Study Part Two

## Key facts

- **NCT ID:** NCT06044467
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-11
- **Primary completion:** 2020-04-27
- **Final completion:** 2020-04-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044467, "The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06044467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*